ABBV $204.95 (-0.64%) Quote details

Establish your trading edge with a set of smart tools for serious trades. Upgrade Account
stock

AbbVie Inc

NYSE | ABBV

204.95

USD

-1.32 (-0.64%)

AT CLOSE (AS OF Apr 2, 2025)

$365B

MARKET CAP

86.31

P/E Ratio

2.39

EPS

$219

52 Week High

$150

52 Week Low

LIFE SCIENCES

Sector

ABBV Chart

1D
Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More
Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More
Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More

ABBV Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field Value (USD)
Gross Profit $8.9B
Total Revenue $54B
Cost Of Revenue $45B
Costof Goods And Services Sold $20B
Operating Income $13B
Selling General And Administrative $13B
Research And Development $8.5B
Operating Expenses $33B
Investment Income Net $540M
Net Interest Income -$2.2B
Interest Income -
Interest Expense $2.2B
Non Interest Income $54B
Other Non Operating Income -$4.7B
Depreciation $752M
Depreciation And Amortization $7.9B
Income Before Tax $6.2B
Income Tax Expense $1.4B
Interest And Debt Expense $2.2B
Net Income From Continuing Operations $4.9B
Comprehensive Income Net Of Tax $4.8B
Ebit $8.5B
Ebitda $16B
Net Income $4.9B

Revenue & Profitability

Earnings Performance

ABBV Financials

yearly Balance Sheet (As of Dec 31, 2023)

Field Value (USD)
Total Assets $135B
Total Current Assets $33B
Cash And Cash Equivalents At Carrying Value $13B
Cash And Short Term Investments $13B
Inventory $4.1B
Current Net Receivables $11B
Total Non Current Assets $102B
Property Plant Equipment $5B
Accumulated Depreciation Amortization Ppe $6.6B
Intangible Assets $88B
Intangible Assets Excluding Goodwill $56B
Goodwill $32B
Investments -
Long Term Investments $304M
Short Term Investments $2M
Other Current Assets $4.9B
Other Non Current Assets $8.5B
Total Liabilities $124B
Total Current Liabilities $38B
Current Accounts Payable $3.7B
Deferred Revenue -
Current Debt $7.2B
Short Term Debt $0
Total Non Current Liabilities $113B
Capital Lease Obligations $27M
Long Term Debt $59B
Current Long Term Debt $7.2B
Long Term Debt Noncurrent -
Short Long Term Debt Total $59B
Other Current Liabilities $27B
Other Non Current Liabilities $32B
Total Shareholder Equity $10B
Treasury Stock $6.5B
Retained Earnings -$1B
Common Stock $18M
Common Stock Shares Outstanding $1.8B

yearly Cash Flow (As of Dec 31, 2023)

Field Value (USD)
Operating Cashflow $23B
Payments For Operating Activities $8.3B
Proceeds From Operating Activities -
Change In Operating Liabilities $3.8B
Change In Operating Assets $539M
Depreciation Depletion And Amortization $8.7B
Capital Expenditures $777M
Change In Receivables -$66M
Change In Inventory $417M
Profit Loss $4.9B
Cashflow From Investment -$2B
Cashflow From Financing -$17B
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock $2B
Payments For Repurchase Of Equity $2B
Payments For Repurchase Of Preferred Stock -
Dividend Payout $11B
Dividend Payout Common Stock $11B
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$1.8B
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $4.9B

yearly Income Statement (As of Dec 31, 2023)

Field Value (USD)
Gross Profit $8.9B
Total Revenue $54B
Cost Of Revenue $45B
Costof Goods And Services Sold $20B
Operating Income $13B
Selling General And Administrative $13B
Research And Development $8.5B
Operating Expenses $33B
Investment Income Net $540M
Net Interest Income -$2.2B
Interest Income -
Interest Expense $2.2B
Non Interest Income $54B
Other Non Operating Income -$4.7B
Depreciation $752M
Depreciation And Amortization $7.9B
Income Before Tax $6.2B
Income Tax Expense $1.4B
Interest And Debt Expense $2.2B
Net Income From Continuing Operations $4.9B
Comprehensive Income Net Of Tax $4.8B
Ebit $8.5B
Ebitda $16B
Net Income $4.9B

Dividends

Field Value
Ex Dividend Date 2025-04-15
Declaration Date 2025-02-13
Record Date 2025-04-15
Payment Date 2025-05-15
Amount 1.64

ABBV Profile

AbbVie Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Discover more tools and features to empower your trading
Explore Features

Quotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.